Rex Clinical Trials LLC — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$853,213	72
2024	Research	$17,550	2
2023	Research	$66	1

Breakdown

Who paid Research payments · program years 2023–2025

Moderna TX, Inc. $420,972 27 payments
GlaxoSmithKline, LLC. $286,064 29 payments
Sanofi US Services Inc. $72,910 9 payments
ITI, Inc. $47,783 7 payments
Genzyme Corporation $25,550 1 payment
Chiesi USA, Inc. $17,550 2 payments

Studies the money was for Research payments · program years 2023–2025

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $395,872 22 payments
A Phase 4, 52-Week (Primary Analysis at 24-Weeks), Randomized, Stratif $215,192 11 payments
A Phase 3A, Observer-Blind, Randomized, Controlled Study to Demonstrat $63,722 16 payments
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies $43,910 8 payments
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype $29,000 1 payment
Evaluate how dupilumab can alter the trajectory of COPD by modifying disease progression $25,550 1 payment
Iti-007-601 $20,283 5 payments
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $17,550 2 payments
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age $14,934 2 payments
Iti-007-421 $13,750 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.